Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Eicosapentaenoic acid and docosahexaenoic acid reduce interleukin-1b-mediated cartilage degradation. | Wann et al. Arthritis Research Therapy 2010 12 R207 http content 12 6 R207 RESEARCH ARTICLE Open Access Eicosapentaenoic acid and docosahexaenoic acid reduce interleukin-1 p-mediated cartilage degradation . _ . . 1. . . 1 . 3 . . . .1 Angus KT Wann Jiten Mistry 1 Emma J Blain3 Adina T Michael-Titus2 Martin M Knight1 Abstract Introduction In inflammatory joint disease such as osteoarthritis OA there is an increased level of proinflammatory cytokines such as interleukin IL -ip. These cytokines stimulate the production of matrix metalloproteinases MMPs which leads to the degradation of the cartilage extracellular matrix and the loss of key structural components such as sulphated glycosaminoglycan sGAG and collagen II. The aim of this study was to examine the therapeutic potential of n-3 polyunsaturated fatty acids PUFAs in an in vitro model of cartilage inflammation. Methods Two specific n-3 compounds were tested namely eicosapentaenoic acid EPA and docosahexaenoic acid DHA each at 1 and 10 pM. Full thickness bovine cartilage explants 5 mm in diameter were cultured for 5 days with or without IL-ip and in the presence or absence of each n-3 compound. The media were replaced every 24 hours and assayed for sGAG content using the 1 9-dimethylmethylene blue DMB method. Chondrocyte viability was determined at the end of the culture period using fluorescence microscopy to visualise cells labelled with calcein AM and ethidium homodimer. Results Treatment with IL-ip 10 produced a large increase in sGAG release compared to untreated controls but with no effect on cell viability which was maintained above 80 for all treatments. In the absence of IL-1p both n-3 compounds induced a mild catabolic response with increased loss of sGAG particularly at 10 pM. By contrast in the presence of IL-1p both EPA and DHA at and 1 pM significantly reduced IL-1p-mediated sGAG loss. The efficacy of the EPA treatment was maintained at approximately 75 .
